Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04685811

Evaluation of PSMA Antagonist Produced by Two Different Methods

Metastatic Prostate Adenocarcinoma Clinical Trial

Official title:
Evaluation of a 68Ga Small Molecule PSMA Antagonist Produced by Two Different Methods

Clinical Trial Summary

Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers. The goal of the study is to evaluate repeatability and equivalence across the different 68Ga-PSMA production methods. This research study is being conducted to assess whether the PET/CT imaging results, as generated from the two different 68Ga production methods, are equivalent.

Clinical Trial Description

Patients with metastatic prostate adenocarcinoma will be enrolled in the study and will undergo two 68Ga-Prostate Specific Membrane Antigen- Positron Emission Tomography (PSMA-PET) scans within 24-48 hours. The difference between the two scans is that the radiotracer used in each scan will be produced with a different method (68Ga-PSMA-cyclotron and 68Ga-PSMA-generator produced). The first scan will occur after a baseline clinical evaluation, which will include a history, physical, and baseline lab draw. After each scan, blood draws will be obtained. The purpose of this study is to evaluate equivalence of two processes to create 68Ga-HBED-PSMA and compare dosimetry, biodistribution and whole body excretion/ metabolism. Furthermore, the research team will perform dynamic analysis of the PET scans to investigate repeatability of whole-body 68Ga-PSMA-generator Ki Patlak imaging against that of conventional whole-body 68Ga-PSMA- SUV imaging and evaluate equivalence of whole-body 68Ga-PSMA Ki Patlak imaging between the two processes to create 68Ga-HBED-PSMA (68GA-PSMA-cyclotron vs. 68Ga-PSMA-generator). Patients will afterwards receive standard of care treatment and follow up imaging. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04685811
Study type Interventional
Source Weill Medical College of Cornell University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date December 9, 2020
Completion date June 30, 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04033432 - sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Not yet recruiting NCT06236139 - Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Recruiting NCT04734730 - Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Phase 2
Recruiting NCT06039371 - Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Phase 2
Withdrawn NCT04781374 - Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05689021 - CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Phase 2
Recruiting NCT05796973 - Measuring Oncological Value of Exercise and Statin Phase 3
Recruiting NCT05054296 - Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring Phase 2
Active, not recruiting NCT03902951 - Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Phase 2
Recruiting NCT05168618 - Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial Phase 2
Recruiting NCT05445609 - Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05479578 - Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase 1
Recruiting NCT05113537 - Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT04754425 - Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT04190446 - Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment Phase 2
Recruiting NCT04471974 - ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT05573789 - Tumor Molecular Profiling in Patients With Prostate Cancer
Active, not recruiting NCT02099864 - Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Phase 2
Suspended NCT03317392 - Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis Phase 1/Phase 2
Active, not recruiting NCT04455750 - A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy Phase 3